• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种针对精神分裂症患者的抑郁评定量表。

A depression rating scale for schizophrenics.

作者信息

Addington D, Addington J, Schissel B

机构信息

University of Calgary, Department of Psychiatry, Foothills Hospital, Calgary, Canada.

出版信息

Schizophr Res. 1990 Jul-Aug;3(4):247-51. doi: 10.1016/0920-9964(90)90005-r.

DOI:10.1016/0920-9964(90)90005-r
PMID:2278986
Abstract

Scales for assessing depression are well developed for non-psychotic populations but have been criticized for being inappropriate for psychotic populations. As a result we have developed a new rating scale for the measurement of depression in schizophrenia based on items selected from the Hamilton Depression Rating Scale and the Present State Examination. The selection was based on a three stage procedure first factor analysis then measures of internal consistency and finally face validity. Ratings of depression were made on 50 acutely ill schizophrenics meeting DSM-III criteria for schizophrenia assessed at two points in time. Our results indicate that several items from both scales form a superior instrument for measuring depression in schizophrenia. The eleven items generated a Cronbach's alpha of 0.84 at time one and 0.89 at time 2.

摘要

评估抑郁症的量表在非精神病患者群体中已得到充分发展,但因不适用于精神病患者群体而受到批评。因此,我们基于从汉密尔顿抑郁量表和现况检查中选取的项目,开发了一种新的评定量表,用于测量精神分裂症患者的抑郁情况。选择过程基于三个阶段:首先进行因素分析,然后测量内部一致性,最后进行表面效度评估。对50名符合DSM-III精神分裂症标准的急性精神分裂症患者在两个时间点进行抑郁评定。我们的结果表明,这两个量表中的几个项目构成了一种用于测量精神分裂症患者抑郁情况的更优工具。这11个项目在第一次测量时的克朗巴赫α系数为0.84,在第二次测量时为0.89。

相似文献

1
A depression rating scale for schizophrenics.一种针对精神分裂症患者的抑郁评定量表。
Schizophr Res. 1990 Jul-Aug;3(4):247-51. doi: 10.1016/0920-9964(90)90005-r.
2
Reliability and validity of a depression rating scale for schizophrenics.精神分裂症患者抑郁评定量表的信度与效度
Schizophr Res. 1992 Mar;6(3):201-8. doi: 10.1016/0920-9964(92)90003-n.
3
Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS).精神分裂症患者卡尔加里抑郁量表(CDSS)的同时效度研究。
J Affect Disord. 2000 May;58(2):107-15. doi: 10.1016/s0165-0327(99)00075-0.
4
Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia.《卡尔加里精神分裂症抑郁量表西班牙语版的跨文化改编与验证》
Schizophr Res. 2004 Jun 1;68(2-3):349-56. doi: 10.1016/S0920-9964(02)00490-5.
5
Calgary Depression Scale for Schizophrenia: a study of the validity of a French-language version in a population of schizophrenic patients.《卡尔加里精神分裂症抑郁量表:法语版在精神分裂症患者群体中的效度研究》
Acta Psychiatr Scand. 1998 Jan;97(1):36-41. doi: 10.1111/j.1600-0447.1998.tb09960.x.
6
Depression dexamethasone nonsuppression and negative symptoms in schizophrenia.精神分裂症中的抑郁、地塞米松不抑制及阴性症状
Can J Psychiatry. 1990 Jun;35(5):430-3. doi: 10.1177/070674379003500512.
7
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale.评估精神分裂症中的抑郁症状: Calgary 精神分裂症抑郁量表与汉密尔顿抑郁评定量表的心理计量学比较。
Psychopathology. 2012;45(5):276-85. doi: 10.1159/000336729. Epub 2012 Jul 12.
8
[Depression scales in schizophrenia: a critical review].[精神分裂症中的抑郁量表:一项批判性综述]
Encephale. 1998 Nov-Dec;24(6):530-40.
9
Psychometric properties of the Japanese version of the Calgary Depression Scale for Schizophrenics.日本版精神分裂症患者卡尔加里抑郁量表的心理测量学特性。
J Nerv Ment Dis. 2000 Apr;188(4):237-9. doi: 10.1097/00005053-200004000-00008.
10
Diagnosis of secondary depression in schizophrenia.精神分裂症继发抑郁的诊断
J Clin Psychiatry. 1985 Nov;46(11 Pt 2):4-8.

引用本文的文献

1
Disruption of consciousness depends on insight in obsessive-compulsive disorder and on positive symptoms in schizophrenia.意识障碍取决于强迫症中的洞察力以及精神分裂症中的阳性症状。
Neurosci Conscious. 2025 Aug 26;2025(1):niaf029. doi: 10.1093/nc/niaf029. eCollection 2025.
2
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.加速药物合作精神分裂症项目参与者的基线临床特征
Schizophr Bull Open. 2025 Aug 25;6(1):sgaf012. doi: 10.1093/schizbullopen/sgaf012. eCollection 2025 Jan.
3
Association Between Urban Upbringing and Cortical Gyrification in Persons with Schizophrenia.
精神分裂症患者的城市成长经历与大脑皮质脑回形成之间的关联
Indian J Psychol Med. 2025 Aug 15:02537176251360933. doi: 10.1177/02537176251360933.
4
Validation of the Romanian version of the brief negative symptom scale in a heterogeneous schizophrenia inpatient sample.罗马尼亚版简明阴性症状量表在异质性精神分裂症住院患者样本中的效度验证
Glob Ment Health (Camb). 2025 Jul 17;12:e85. doi: 10.1017/gmh.2025.10037. eCollection 2025.
5
Non-Linear Relationships of Loneliness with Age in People Living with Schizophrenia and Non-Psychiatric Comparison Participants: Relations non linéaires entre la solitude et l'âge chez les personnes atteintes de schizophrénie et les personnes n'ayant aucun antécédent de maladie psychiatrique.精神分裂症患者及非精神疾病对照参与者中孤独感与年龄的非线性关系:精神分裂症患者及无精神疾病史者中孤独感与年龄的非线性关系
Can J Psychiatry. 2025 Jul 28:7067437251355636. doi: 10.1177/07067437251355636.
6
An exploratory study of the relevance of therapy format and therapist' training in individual cognitive behavioral therapy for psychosis.针对精神病的个体认知行为疗法中治疗形式及治疗师培训相关性的探索性研究。
Front Psychiatry. 2025 Jul 2;16:1527549. doi: 10.3389/fpsyt.2025.1527549. eCollection 2025.
7
Psychometric evaluation of the Persian version of the Beliefs About Voices Questionnaire: revised in patients with schizophrenia spectrum disorders.精神分裂症谱系障碍患者中波斯语版《幻听信念问卷》修订版的心理测量学评估
BMC Psychiatry. 2025 Jul 1;25(1):667. doi: 10.1186/s12888-025-07080-z.
8
Negative symptomatology and clozapine-induced obsessive-compulsive symptoms: a cross-sectional analysis.阴性症状学与氯氮平诱发的强迫症状:一项横断面分析。
Eur Arch Psychiatry Clin Neurosci. 2025 May 16. doi: 10.1007/s00406-025-02021-z.
9
Subtyping first-episode psychosis based on longitudinal symptom trajectories using machine learning.基于机器学习的纵向症状轨迹对首发精神病进行亚型分类。
Npj Ment Health Res. 2025 May 15;4(1):18. doi: 10.1038/s44184-025-00129-7.
10
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目中的样本确定与临床结局指标
Schizophrenia (Heidelb). 2025 Apr 3;11(1):54. doi: 10.1038/s41537-025-00556-7.